PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of virLink to Publisher's site
 
J Gen Virol. 2009 June; 90(Pt 6): 1461–1470.
PMCID: PMC2885060

Murid herpesvirus-4 lacking thymidine kinase reveals route-dependent requirements for host colonization

Abstract

Gammaherpesviruses infect at least 90 % of the world's population. Infection control is difficult, in part because some fundamental features of host colonization remain unknown, for example whether normal latency establishment requires viral lytic functions. Since human gammaherpesviruses have narrow species tropisms, answering such questions requires animal models. Murid herpesvirus-4 (MuHV-4) provides one of the most tractable. MuHV-4 genomes delivered to the lung or peritoneum persist without lytic replication. However, they fail to disseminate systemically, suggesting that the outcome is inoculation route-dependent. After upper respiratory tract inoculation, MuHV-4 infects mice without involving the lungs or peritoneum. We examined whether host entry by this less invasive route requires the viral thymidine kinase (TK), a gene classically essential for lytic replication in terminally differentiated cells. MuHV-4 TK knockouts delivered to the lung or peritoneum were attenuated but still reached lymphoid tissue. In contrast, TK knockouts delivered to the upper respiratory tract largely failed to establish a detectable infection. Therefore TK, and by implication lytic replication, is required for MuHV-4 to establish a significant infection by a non-invasive route.

INTRODUCTION

Gammaherpesviruses persist in lymphocytes and use lymphocyte proliferation to amplify their latent genome loads. Viral immune evasion (Stevenson, 2004) makes this process hard to stop. It also makes long-term infection hard to clear. The initial establishment of lymphocyte infection by virions entering a naive host is therefore a key target for infection control.

Gammaherpesviruses, like many other mammalian herpesviruses, are thought to be transmitted via saliva (Yao et al., 1985). Epstein–Barr virus (EBV), as the most intensively studied example, provides something of an archetype. It infects epithelial cells poorly in vitro, and has therefore been proposed to infect in vivo by saliva reaching B cells in tonsillar crypts (Faulkner et al., 2000; Thorley-Lawson, 2001), where infection is abundant during infectious mononucleosis. However, infectious mononucleosis occurs at least 1 month after actual transmission (Hoagland, 1964). Therefore, tonsillar infection could just as easily represent EBV exit. One prediction of the direct B cell infection hypothesis, that antibodies to gp350, which block B cell infection in vitro (Thorley-Lawson & Geilinger, 1980), would reduce host entry in vivo, was not fulfilled (Sokal et al., 2007). Blocking gp350-independent (non-B cell) EBV infection (Janz et al., 2000) would require a different vaccine. Therefore it is important for infection control to understand how gammaherpesviruses enter their hosts.

Both EBV and the other known human gammaherpesvirus, the Kaposi's sarcoma-associated herpesvirus (KSHV), are difficult to study in vivo. Therefore the small animal model provided by murid herpesvirus-4 (MuHV-4) (Nash et al., 2001; Stevenson & Efstathiou, 2005) provides a useful means of analysing gammaherpesvirus pathogenesis. MuHV-4 is more closely related to KSHV than to EBV, but epithelial and B cell tropisms are common to all three viruses, and presumably pre-date their divergence; similar routes of host colonization are therefore likely. The main natural host of MuHV-4 appears to be yellow-necked mice (Apodemus flavicollis) (Kozuch et al., 1993). However, it behaves like a natural parasite also in Mus musculus-derived laboratory strains, persisting without disease unless there is immunosuppression (Virgin & Speck, 1999). Moreover its immune-evasion genes, typically the most host-restricted of viral functions, seem to work normally in laboratory mice, even showing strain specificity (Boname et al., 2004). MuHV-4 infection of laboratory mice therefore seems to offer a reasonable physiological model of gammaherpesvirus infection.

In the standard intranasal MuHV-4 infection model, deep general anaesthesia and a large inoculum volume are used to deliver virions directly to the lung alveoli, where lytic replication occurs. Vaccination against viral lytic antigens largely blocks this replication, but does not block latency establishment (Stevenson et al., 1999). Thymidine kinase (TK)-deficient mutants show a severe lytic replication defect in lungs, but still establish normal long-term latency in spleens (Coleman et al., 2003). The establishment of B-cell latency after lung infection is therefore independent of the extent of viral lytic replication. Completely replication-deficient MuHV-4 genomes can also persist after delivery to the lung alveoli or the peritoneal cavity. Thus, ORF6 MuHV-4 infects peritoneal macrophages, but not splenic B cells after intraperitoneal inoculation (Tibbetts et al., 2006); ORF31 MuHV-4 reaches the spleen after intraperitoneal inoculation, but not after lung inoculation (Kayhan et al., 2007); and ORF50 MuHV-4 colonizes B cells in the lung, but not in the spleen, after lung inoculation (Moser et al., 2006). This last result is hard to understand, because B cells infected in the lung should recirculate to the spleen, and it is possible that some of the PCR-based assays of host colonization used with replication-deficient mutants detected input viral debris rather than bona fide infected cells. The conservative conclusion would be that systemic lymphoid tissue is not readily accessible to MuHV-4 delivered by the intranasal route. Nevertheless, all these studies concluded that replication-deficient viruses established significant persistent infections.

The value of an animal model depends not just on sophisticated genetic techniques, but on ecological considerations such as how virions might normally enter their hosts. Intranasal virus inoculation is more likely than intraperitoneal inoculation to reflect natural infection. However, direct virus delivery to the lung may also be misleading. MuHV-4 given intranasally in low volumes without anaesthesia replicates lytically just in the nose (Milho et al., 2009). A persistent, systemic infection is nevertheless robustly established even with low-dose inoculations. In contrast, orally delivered virus is very poorly infectious (Milho et al., 2009). Therefore the nose, but not the lung, is a plausible natural portal of host entry.

Distinguishing upper and lower respiratory tract entry routes is important, as they involve very different epithelial surfaces. In order to explore further the requirements of MuHV-4 for host colonization via the upper respiratory tract, we infected mice with TK-deficient mutants (Coleman et al., 2003). We used these in preference to completely replication-deficient mutants for two reasons: first, we are interested in viral functions that are specifically required for replication in vivo, and TK MuHV-4 replicates normally in vitro; second, the normal in vitro replication of TK mutants places less reliance on measuring host colonization by viral DNA loads, which do not distinguish viable genomes from non-infectious debris. In contrast to lung or peritoneal infections, TK virions delivered to the upper respiratory tract failed to establish a detectable infection. The herpes simplex virus (HSV) TK is largely redundant for epithelial infection, but is essential for lytic replication in terminally differentiated neurons (Efstathiou et al., 1989; Coen et al., 1989; Valyi-Nagy et al., 1994). Therefore, MuHV-4 may have to pass through terminally differentiated cells when infecting via the nose, suggesting that TK-based therapies have the potential to block gammaherpesvirus spread.

METHODS

Mice.

Female BALB/c mice were infected with MuHV-4 when 6–12 weeks old. Intranasal infections were either in 30 μl under deep general anaesthesia (lower respiratory tract infection) or in 5 μl under light anaesthesia (upper respiratory tract infection). Intraperitoneal infections were in 300 μl. For luciferase imaging, mice were given intraperitoneal injections of luciferin (2 mg per mouse), anaesthetized with isoflurane, then scanned with an IVIS Lumina (Caliper Life Sciences). Quantitative comparisons used the maximum radiance (photons s−1 cm−2 steradian−1) over each region of interest, relative to a negative control region. All experiments conformed to local animal ethics regulations and Home Office Project Licence 80/1992.

Cells.

BHK-21, 293T, NIH-3T3-CRE (Stevenson et al., 2002) and RAW-264 cells were propagated in Dulbecco's modified Eagle's medium (Invitrogen), supplemented with 2 mM glutamine, 100 U penicillin ml−1, 100 μg streptomycin ml−1 and 10 % fetal calf serum. Peritoneal cells were obtained by a post-mortem injection and aspiration of 10 ml PBS. Typically 50 % of the cells recovered were macrophages (CD19F4/80+ by flow cytometry). The remainder were B cells (CD19+F4/80). Selection by adherence to plastic increased the proportion of macrophages to >90 %.

Viruses.

The TKKAN mutant, its revertant, and the TKDEL mutant have been described previously (Coleman et al., 2003). We generated LUC+ TK knockouts by shuttling the M3-LUC reporter construct (Milho et al., 2009) into the TKKAN bacterial artificial chromosome (BAC). We also combined the TKKAN mutation with enhanced GFP (eGFP)-tagged gM (Smith et al., 2007) and with gp150 disruption (M7STOP) (de Lima et al., 2004). The integrity of each recombinant BAC was confirmed by restriction endonuclease mapping. Infectious virions were recovered by transfecting BAC DNA into BHK-21 cells. For in vivo experiments, the loxP-flanked viral BAC/eGFP cassette was removed by passage through NIH-3T3-CRE cells. Virus stocks were grown in BHK-21 cells (de Lima et al., 2004).

Infectivity assays.

Virus stocks were titrated by plaque assay on BHK-21 cells (de Lima et al., 2004): cell monolayers were incubated with virus (2 h, 37 °C), overlaid with 0.3 % carboxymethylcellulose, and 4 days later fixed and stained for plaque counting. Infectious virus in ex vivo tissues was measured by plaque assay of freeze–thawed tissue homogenates. To titre noses, we removed a block of tissue bounded by (i.e. not including) anteriorly the cartilaginous tip of the nose, posteriorly the orbits, laterally the zygomatic arches, ventrally the palate and dorsally the nasal bones. This region contained all the luciferase signal measureable by ex vivo charge-coupled device (CCD) camera scanning. Bone fragments were discarded after homogenization. The latent virus in ex vivo tissues was measured by infectious centre assay (de Lima et al., 2004): spleen or superficial cervical lymph node (SCLN) suspensions were co-cultured with BHK-21 cells, then fixed and stained for plaque counting after 4 days. Pre-formed infectious virus titres in lymphoid tissue, as measured by plaque assay of freeze–thawed cells, were always <1 % of infectious centre assay titres.

Viral genome quantification.

Viral genome loads were measured by real-time PCR (Gaspar et al., 2008). DNA (50–80 ng) was extracted from ex vivo organs (Wizard genomic DNA purification kit; Promega) and used to amplify MuHV-4 genomic co-ordinates 4166–4252 (Rotor Gene 3000; Corbett Research). The PCR products were quantified by hybridization with a Taqman probe (genomic coordinates 4218–4189) and converted to genome copies by comparison with a standard curve of cloned plasmid template, amplified in parallel. Cellular DNA was quantified in parallel by amplifying part of the adenosine phosphoribosyltransferase gene (forward primer 5′-GGGGCAAAACCAAAAAAGGA-3′, reverse primer 5′-TGTGTGTGGGGCCTGAGTC-3′, probe 5′-TGCCTAAACACAAGCATCCCTACCTCAA-3′).

ELISA.

MuHV-4 virions were recovered from infected BHK-21 cell supernatants by ultracentrifugation, disrupted with 0.05 % Triton X-100 in 50 mM sodium carbonate buffer (pH 8.5), and coated (18 h, 4 °C) onto Maxisorp ELISA plates (Nalgene Nunc). The plates were washed three times in PBS/0.1 % Tween-20, blocked with 2 % BSA in PBS/0.1 % Tween-20 (1 h, 23 °C), then incubated with threefold serum dilutions from MuHV-4-exposed mice (1 h, 23 °C). The plates were then washed four times in PBS/0.1 % Tween-20, incubated (1 h, 23 °C) with alkaline phosphatase-conjugated goat anti-mouse IgG-Fc pAb (Sigma), washed five times, and developed with nitrophenylphosphate (Sigma). Absorbance was read at 405 nm (Bio-Rad Benchmark ELISA plate reader).

RESULTS

Total respiratory tract infection by TK MuHV-4

MuHV-4 TK knockouts have a severe lytic replication defect in lungs as measured by plaque assay (Coleman et al., 2003). Viral luciferase expression provides an alternative means of tracking infection that can be applied to live mice (Milho et al., 2009). We expressed luciferase from an early lytic MuHV-4 promoter, making it a subtly different readout to plaque assays, which also require viral late functions to form infectious virions. Since TK is thought to function mainly in viral DNA replication, luciferase expression should provide a more sensitive measure of host colonization by TK mutants. Like other TK knockouts (Coleman et al., 2003), luciferase+TK MuHV-4 replicated normally in vitro. Its TK status was confirmed by staining infected cells with the TK-specific mAb CS-4A5 (May et al., 2008) (data not shown).

After intranasal virus inoculation (103 p.f.u.) under deep anaesthesia (Fig. 1), luciferase expression was detectable in the lungs of mice given either TK+ or TK viruses. However, the TK mutant showed no luciferase signal in the nose (Fig. 1a, bb).). Therefore the TK-dependent reduction in early lytic gene expression, presumably reflecting reduced lytic spread, was greater in noses than in lungs. Infectious TK MuHV-4 was undetectable in both noses and lungs by plaque assay (Fig. 1c).

Fig. 1.
Luciferase imaging of TK MuHV-4 infection in the lower respiratory tract. (a) Mice were infected intranasally (103 p.f.u., 30 μl) under general anaesthesia with TK+ or TK ...

Upper respiratory tract infection by TK MuHV-4

We explored the TK-dependent upper respiratory tract infection defect further by low-volume intranasal inoculation (Fig. 2). This delivers virus more accurately to the nose, because none of the inoculum is aspirated into the lung. Again there was no evidence of luciferase expression in the nose by the TK knockout (Fig. 2a, bb).). Nor was there a later signal in the neck (Fig. 2c), which corresponds to viral latency establishment in the SCLN (Milho et al., 2009). Therefore, TK MuHV-4 appeared not to establish a significant infection via the upper respiratory tract.

Fig. 2.
TK MuHV-4 infection of the upper respiratory tract. (a) Mice were inoculated intranasally with TK+ or TK luciferase+ MuHV-4 (103 p.f.u. in 5 μl), then imaged for ...

TK MuHV-4 delivered to the lung establishes latency despite its lytic replication defect: reactivatable virus is present in the spleen and antibodies to viral lytic antigens are present in serum by 1 month post-inoculation (Coleman et al., 2003). Given the minimal primary lytic spread of TK mutants, this antibody response presumably reflects latency-associated lymphoproliferation, followed by reactivation. At any rate, it provides a sensitive measure of host colonization. TK MuHV-4 delivered to the upper respiratory tract had elicited no detectable antibody response after 1 month (Fig. 3a). Infectious centres were also undetectable in spleens or SCLN (Fig. 3b), and only one mouse showed a viral genome PCR signal above background levels (Fig. 3c). Even that signal was very low, suggesting sample contamination or the detection of input viral debris transported to draining lymph nodes. Splenic PCR signals, which are probably a more stringent test of significant host colonization, were all negative. Therefore, TK MuHV-4 seemed to infect mice poorly via the upper respiratory tract.

Fig. 3.
No late colonization of mice by TK MuHV-4 delivered to the upper respiratory tract. (a) Mice were inoculated intranasally (103 p.f.u., 5 μl) with TK+ or TK luciferase+ ...

We then tested our original, luciferase TK knockouts (TKKAN, TKDEL) for host colonization via the upper respiratory tract (Fig. 4). We also increased the inoculation dose to 104 p.f.u. so as to test maximally any resistance to infection. This confirmed the finding with the luciferase+ TK mutant: only two out of ten mice exposed to high dose TK MuHV-4 had detectable virus by infectious centre assay of spleens (Fig. 4a), and only three out of ten had detectable antibody responses (Fig. 4b), whereas all control mice were infected. As 10 p.f.u. wild-type MuHV-4 readily infects mice via the upper respiratory tract (Milho et al., 2009), TK knockouts were at least 100-fold less capable of establishing a detectable infection. Comparing different doses of TK+ and TK viruses (Fig. 4c), and assaying infection by ELISA of serum for MuHV-4-specific IgG at 1 month post-infection (the most sensitive measure), showed TK infection to be inefficient via either the upper or the lower respiratory tract. Upper respiratory tract TK infection appeared to be less efficient, but the difference between inoculation routes did not reach statistical significance.

Fig. 4.
Analysis of infection by luciferase TK mutants. (a) Mice were inoculated intranasally (104 p.f.u., 5 μl) with TK+ (wild-type or revertant) or TK viruses ...

Peritoneal infection by TK MuHV-4

Several studies of host colonization by replication-deficient MuHV-4 mutants have used intraperitoneal inoculation. For the purpose of comparison, therefore, we also looked at this route of infection with TK mutants (Fig. 5). We first tested our published TKKAN virus by the standard infectious centre assay of spleens and peritoneal macrophages (Fig. 5a). Some infectivity was recoverable from spleens, although at least tenfold less than with TK+ controls. No TK infectivity was recovered from peritoneal macrophages. Real-time PCR showed relatively normal TK viral genome loads in peritoneal cells and spleens (Fig. 5b). Therefore, the low plaque titres of the TKKAN mutant appeared to reflect mainly poor infectious virion production. Live imaging of infected cells (Fig. 5c, dd)) supported this idea, with relatively little TK-dependent deficit.

Fig. 5.
Intraperitoneal infection by TK MuHV-4. (a) Mice were infected intraperitoneally (103 p.f.u.) with TK+ (WT, REV) or TK (TKKAN) MuHV-4. ...

We defined the sources of luciferase signals by ex vivo imaging of dissected organs (Fig. 6). TK+ MuHV-4 showed widespread peritoneal infection, with luciferase expression in intestines, spleen, reproductive tract, diaphragm, adrenals and pancreas (Fig. 6a). The apparent lack of kidney, liver or spleen signals in Fig. 6(a) reflects only that the image sensitivity was set low to keep the strong reproductive tract signal on scale – none of these organs was completely luciferase-negative. Intraperitoneal TK luciferase signals were generally lower than wild-type, but again no peritoneal organs were consistently luciferase-negative. Therefore, the pattern was very different from that for upper respiratory tract infection, where the noses of mice given intranasal TK MuHV-4 were always luciferase-negative. The strongest and most consistent intraperitoneal TK luciferase signals, as with TK+, were those of the reproductive tract, omentum and diaphragm. Fig. 6(b) shows quantitative comparisons of four to six mice per group.

Fig. 6.
Intraperitoneal infection by TK MuHV-4: individual organs. (a) Mice were infected intraperitoneally with TK+ or TK luciferase+ MuHV-4 (103 p.f.u.), and 5 days later imaged ...

Infectious virus (TK+ or TK) was hard to recover from the omentum because the associated fat was toxic to BHK-21 cells, and infectious virus was recovered only inconsistently from the diaphragm. The reproductive tract was the most reliable source of both TK+ and TK infectious virions. The spleen also yielded infectious TK virions, as before (Fig. 5a). Both organs showed substantially greater TK-dependent virion production defects than luciferase expression defects. The kidneys and adrenals were positive only for TK+ virions. Nevertheless, TK mutants remained infectious by the intraperitoneal route.

Macrophage infection by TK MuHV-4

Since peritoneal macrophages showed no sign of producing infectious TK virions, we used them to define further the nature of the TK-dependent infection defect (Fig. 7). Growth curves showed poor TK virion production by primary peritoneal macrophages, but not by the transformed monocyte/macrophage cell line RAW-264 (Fig. 7a). TK knockouts also failed to replicate in bone-marrow-derived dendritic cells (data not shown). TK virion entry into peritoneal macrophages did not seem to be impaired, as, for a given level of viral eGFP expression in 293T cells, eGFP expression in peritoneal macrophages was similar between TK and TK+ viruses (Fig. 7b). We have shown previously that this viral eGFP expression is independent of lytic replication (Smith et al., 2007).

Fig. 7.
Macrophage infection by TK+ and TK MuHV-4. (a) Peritoneal macrophages from naive mice or RAW-264 cells were infected (0.01 p.f.u. per cell, 2 h) with TK+ (wild-type or revertant) ...

MuHV-4 typically infects macrophages tenfold less efficiently than it infects fibroblasts, presumably because macrophages express only low levels of the heparan sulfate that MuHV-4 requires for cell binding (Gillet et al., 2007). Therefore, it was possible that a general inefficiency of entry masked an additional TK-dependent defect. We addressed this by disrupting the MuHV-4 M7 ORF, which encodes gp150. gp150 virions are heparan sulfate-independent and consequently infect macrophages as efficiently as they infect fibroblasts (de Lima et al., 2004). Viral eGFP expression in peritoneal macrophages on an M7 virus background remained TK-independent (Fig. 7c).

Immune fluorescence of ex vivo peritoneal macrophage infections (Fig. 7d) showed that TK+ and TK virions were both endocytosed (cytoplasmic glycoprotein and capsid staining), but that only TK+ virions gave new late lytic gene expression (nuclear capsid staining). This result was consistent with TK MuHV-4 infecting but then failing to replicate in peritoneal macrophages in vivo (Fig. 5). Therefore, the TK-dependent macrophage infection defect matched the pattern expected for a virus not producing enough phosphorylated thymidine to replicate in terminally differentiated cells.

DISCUSSION

Our aim in analysing gammaherpesvirus host entry has been to reveal new targets for infection control. We showed here that MuHV-4 requires its TK to establish a significant infection of mice via the upper respiratory tract. More invasive infections were less TK-dependent, but they are less physiological. HSV requires its TK to replicate in terminally differentiated neurons. Gammaherpesvirus TKs are not necessarily the same, but TK MuHV-4 showed a macrophage infection defect consistent with impaired viral DNA replication in terminally differentiated cells. A similar requirement for host colonization by human gammaherpesviruses would make their lytic genes potential targets for infection control.

The phenotype of TK MuHV-4 raised some general questions about gammaherpesvirus host entry. We assume that TK virions still infected cells in the upper respiratory tract, but that the number of cells supporting early lytic gene expression was insufficient for a detectable luciferase signal and without TK, infection did not spread. This would make B cells an unlikely primary target for incoming virions, as TK mutants can both replicate in B cells and drive their proliferation (Coleman et al., 2003). The poor in vitro binding of cell-free MuHV-4 virions to B cells (Gillet & Stevenson, 2007) would also argue against direct infection in vivo. The poor replication of TK MuHV-4 in macrophages could explain TK-dependent host entry if macrophages were a significant primary target. However, cell-free virions also infect macrophages rather poorly (Rosa et al., 2007), and it is unclear what proportion of nasal antigens are sampled by macrophages or dendritic cells. Macrophages are a more plausible primary target in lung alveoli and in the peritoneal cavity, where they have an important scavenging function, but infection in these sites must be considered atypical.

Epithelial cells remain a plausible primary target. However, any epithelial entry model must explain how MuHV-4 virions, which are highly heparan sulfate-dependent in vitro, cope with epithelial heparan sulfate being predominantly basolateral in vivo (Hayashi et al., 1987). The failure of wild-type MuHV-4 to infect mice orally (Milho et al., 2009) also argues for a more anatomically restricted target. Therefore epithelial entry is far from certain. One possibility suggested by the phenotype of TK HSV (Efstathiou et al., 1989; Coen et al., 1989; Valyi-Nagy et al., 1994) is that incoming MuHV-4 infects olfactory neurons. These display heparan sulfate on syndecan-3 (Raulo et al., 1994) and engage in environmental sampling. However, TK might be also required simply because the accessible epithelial cells are terminally differentiated. While TK HSV shows only a mild epithelial replication defect, experimental HSV infection involves deliberate scarification that would stimulate local cell division; the normal state of most cells is quiescence. Notably, we recovered infectious TK virions from only the reproductive tract and spleen, where mitotic rates are relatively high. Therefore further analysis is required to identify precisely where in the upper respiratory tract host colonization by TK virions fails.

Whatever cell type MuHV-4 first targets, nasal host entry makes sense in its seclusion from any salivary route of virion exit. All viruses, being non-motile, must somehow combine efficient capture for host entry with efficient release for exit. Unlike the gut, the respiratory tract presents an anatomical dead end, necessitating bidirectional traffic. Epidemic respiratory viruses manage this by replicating to high titre, causing epithelial destruction, and stimulating sneezing and coughing. Herpesviruses, in contrast, rely on the chronic, asymptomatic shedding of low virion numbers. MuHV-4-infected cells show reduced heparan sulfate expression (de Lima et al., 2004) and secrete gp70 to block local heparan sulfate rebinding (Gillet et al., 2007), but these mechanisms are unlikely to operate beyond the millimetre (100-cell diameter) scale; host exit means travelling centimetres. Alphaherpesviruses have contrived cutaneous exit routes that are anatomically distinct from mucosal entry. Nasal entry and salivary exit could achieve the same for gammaherpesviruses. Such a scheme is perhaps less obvious for EBV and KSHV, because human noses are used less than those of rodents, but it begs to be explored.

Acknowledgments

We thank Stacey Efstathiou and Gabrielle Belz for helpful discussions. P. G. S. is a Wellcome Trust Senior Clinical Fellow (GR076956MA). This work was also supported by Medical Research Council grant G0701185 and by a Royal Society international short-term visit grant to P. G. S.

References

  • Boname, J. M., de Lima, B. D., Lehner, P. J. & Stevenson, P. G. (2004). Viral degradation of the MHC class I peptide loading complex. Immunity 20, 305–317. [PubMed]
  • Coen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, C. L., Schaffer, P. A., Tyler, K. L. & Knipe, D. M. (1989). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 86, 4736–4740. [PubMed]
  • Coleman, H. M., de Lima, B., Morton, V. & Stevenson, P. G. (2003). Murine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latency. J Virol 77, 2410–2417. [PMC free article] [PubMed]
  • de Lima, B. D., May, J. S. & Stevenson, P. G. (2004). Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 78, 5103–5112. [PMC free article] [PubMed]
  • Efstathiou, S., Kemp, S., Darby, G. & Minson, A. C. (1989). The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol 70, 869–879. [PubMed]
  • Faulkner, G. C., Krajewski, A. S. & Crawford, D. H. (2000). The ins and outs of EBV infection. Trends Microbiol 8, 185–189. [PubMed]
  • Gaspar, M., Gill, M. B., Loesing, J. B., May, J. S. & Stevenson, P. G. (2008). Multiple functions for ORF75c in murid herpesvirus-4 infection. PLoS One 3, e2781. [PMC free article] [PubMed]
  • Gillet, L. & Stevenson, P. G. (2007). Evidence for a multiprotein gamma-2 herpesvirus entry complex. J Virol 81, 13082–13091. [PMC free article] [PubMed]
  • Gillet, L., Adler, H. & Stevenson, P. G. (2007). Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection. PLoS One 2, e347. [PMC free article] [PubMed]
  • Hayashi, K., Hayashi, M., Jalkanen, M., Firestone, J. H., Trelstad, R. L. & Bernfield, M. (1987). Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem 35, 1079–1088. [PubMed]
  • Hoagland, R. J. (1964). The incubation period of infectious mononucleosis. Am J Public Health Nations Health 54, 1699–1705. [PubMed]
  • Janz, A., Oezel, M., Kurzeder, C., Mautner, J., Pich, D., Kost, M., Hammerschmidt, W. & Delecluse, H. J. (2000). Infectious Epstein–Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 74, 10142–10152. [PMC free article] [PubMed]
  • Kayhan, B., Yager, E. J., Lanzer, K., Cookenham, T., Jia, Q., Wu, T. T., Woodland, D. L., Sun, R. & Blackman, M. A. (2007). A replication-deficient murine γ-herpesvirus blocked in late viral gene expression can establish latency and elicit protective cellular immunity. J Immunol 179, 8392–8402. [PubMed]
  • Kozuch, O., Reichel, M., Lesso, J., Remenová, A., Labuda, M., Lysy, J. & Mistríková, J. (1993). Further isolation of murine herpesviruses from small mammals in southwestern Slovakia. Acta Virol 37, 101–105. [PubMed]
  • May, J. S., Smith, C. M., Gill, M. B. & Stevenson, P. G. (2008). An essential role for the proximal but not the distal cytoplasmic tail of glycoprotein M in murid herpesvirus 4 infection. PLoS One 3, e2131. [PMC free article] [PubMed]
  • Milho, R., Smith, C. M., Marques, S., Alenquer, M., May, J. S., Gillet, L., Gaspar, M., Efstathiou, S., Simas, J. P. & Stevenson, P. G. (2009). In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 90, 21–32. [PMC free article] [PubMed]
  • Moser, J. M., Farrell, M. L., Krug, L. T., Upton, J. W. & Speck, S. H. (2006). A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge. J Virol 80, 1592–1598. [PMC free article] [PubMed]
  • Nash, A. A., Dutia, B. M., Stewart, J. P. & Davison, A. J. (2001). Natural history of murine γ-herpesvirus infection. Philos Trans R Soc Lond B Biol Sci 356, 569–579. [PMC free article] [PubMed]
  • Raulo, E., Chernousov, M. A., Carey, D. J., Nolo, R. & Rauvala, H. (1994). Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J Biol Chem 269, 12999–13004. [PubMed]
  • Rosa, G. T., Gillet, L., Smith, C. M., de Lima, B. D. & Stevenson, P. G. (2007). IgG Fc receptors provide an alternative infection route for murine gamma-herpesvirus-68. PLoS One 2, e560. [PMC free article] [PubMed]
  • Smith, C. M., Gill, M. B., May, J. S. & Stevenson, P. G. (2007). Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells. PLoS One 2, e1048. [PMC free article] [PubMed]
  • Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F. & Denis, M. (2007). Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J Infect Dis 196, 1749–1753. [PubMed]
  • Stevenson, P. G. (2004). Immune evasion by gamma-herpesviruses. Curr Opin Immunol 16, 456–462. [PubMed]
  • Stevenson, P. G. & Efstathiou, S. (2005). Immune mechanisms in murine gammaherpesvirus-68 infection. Viral Immunol 18, 445–456. [PubMed]
  • Stevenson, P. G., Belz, G. T., Castrucci, M. R., Altman, J. D. & Doherty, P. C. (1999). A γ-herpesvirus sneaks through a CD8+ T cell response primed to a lytic-phase epitope. Proc Natl Acad Sci U S A 96, 9281–9286. [PubMed]
  • Stevenson, P. G., May, J. S., Smith, X. G., Marques, S., Adler, H., Koszinowski, U. H., Simas, J. P. & Efstathiou, S. (2002). K3-mediated evasion of CD8+ T cells aids amplification of a latent γ-herpesvirus. Nat Immunol 3, 733–740. [PubMed]
  • Thorley-Lawson, D. A. (2001). Epstein–Barr virus: exploiting the immune system. Nat Rev Immunol 1, 75–82. [PubMed]
  • Thorley-Lawson, D. A. & Geilinger, K. (1980). Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein–Barr virus neutralize infectivity. Proc Natl Acad Sci U S A 77, 5307–5311. [PubMed]
  • Tibbetts, S. A., Suarez, F., Steed, A. L., Simmons, J. A. & Virgin, H. W. (2006). A γ-herpesvirus deficient in replication establishes chronic infection in vivo and is impervious to restriction by adaptive immune cells. Virology 353, 210–219. [PubMed]
  • Valyi-Nagy, T., Gesser, R. M., Raengsakulrach, B., Deshmane, S. L., Randazzo, B. P., Dillner, A. J. & Fraser, N. W. (1994). A thymidine kinase-negative HSV-1 strain establishes a persistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement. Virology 199, 484–490. [PubMed]
  • Virgin, H. W. & Speck, S. H. (1999). Unraveling immunity to γ-herpesviruses: a new model for understanding the role of immunity in chronic virus infection. Curr Opin Immunol 11, 371–379. [PubMed]
  • Yao, Q. Y., Rickinson, A. B. & Epstein, M. A. (1985). A re-examination of the Epstein–Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35, 35–42. [PubMed]

Articles from The Journal of General Virology are provided here courtesy of Society for General Microbiology